Similar agonistic approaches may be possible for targeting Fas, but preclinical models have revealed a potential unexpected benefit of blocking Fas: survival of tumor-infiltrating T cells, which may, in turn, enhance the efficacy of immunologic checkpoint blockade (190). The gene discussed is FAS; the disease is neoplasm.